Samsung Biologics, BioEleven partner on cancer immunotherapy

By The Science Advisory Board staff writers

October 19, 2020 -- Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.

BN-101A blocks programmed cell death ligand 1 (PD-L1) function and promotes anti-cancer T- cell activity. The drug has been validated in preclinical models and BioEleven plans to enter a global phase I clinical trial by 2022.

Under the agreement, Samsung Biologics will provide the full scope of its development services including cell line development, process development, nonclinicial and clinical material manufacturing, and regulatory filing support.

Samsung Biologics, Kanaph Therapeutics partner on retinal disease therapy
Samsung Biologics and Kanaph Therapeutics are partnering on the development of KNP-301, a bispecific Fc fusion protein to treat retinal diseases.
PharmAbcine, Samsung Biologics expand partnership
PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody...
Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...
Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2020

Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
International Society for Pharmaceutical Engineering Annual Meeting
October 30 - November 2
Orlando, Florida United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter